On July 17th of 2019, the FDA made their stance on CBD clear.
They’ve expressed concerns about the:
“many unanswered questions about the science, safety, and quality of products containing CBD.”
Currently the FDA has only recognized the prescription drug Epidiolex, which is used for rare forms of epilepsy.
The FDA does make a solid point in the claim that:
“Some CBD Products are Being Marketed with Unproven Medical Claims”
Unfortunately, much like other supplements, the inability for the FDA to do a full overview of each company is what causes there to be issues with exaggerated and unproven claims.
Fortunately, there are peer reviewed clinical studies which outline what the possible health benefits are of CBD.
In this 2016 study, the effects measured for epilepsy control with remarkable results:
Yet another 2015 study showed a remarkable impact on pain relief.
A grand total of 78 studies on CBD oil are currently up for viewing on Pub Med.
The clear showcase here is that certain conditions show a promising improvement through CBD use.
Read the full FDA statement by clicking below
